Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| RTSN | 3 | neutral | 2/10 | Sabine Bisson, the Chief Operating Officer of Retension Pharmaceuticals, filed a Form 3 initial statement of beneficial | Oct 8, 2026 |
| RTSN | 3 | neutral | 2/10 | Franklin M. Berger filed an initial Statement of Beneficial Ownership (Form 3) with Retension Pharmaceuticals, Inc., dis | Oct 8, 2026 |
| RTSN | 3 | neutral | 2/10 | Michael J. Berendt filed an initial statement of beneficial ownership (Form 3) with Retension Pharmaceuticals, Inc., dis | Oct 8, 2026 |
| VTVT | SC 13G/A | neutral | 3/10 | Millennium Management LLC and affiliated entities filed an amended Schedule 13G, disclosing a 8.7% beneficial ownership | Oct 8, 2026 |
| COLL | SC 13G/A | neutral | 4/10 | Millennium Management (via Integrated Core Strategies) filed an amended Schedule 13G disclosing a 7.4% passive stake in | Oct 8, 2026 |
| XFOR | 8-K | mixed | 6/10 | X4 Pharmaceuticals entered into a $150M senior secured term loan facility with K2 HealthVentures, receiving an $80M firs | Oct 8, 2026 |
| FBLG | 8-K | bearish | 6/10 | FibroBiologics issued a $1.2M convertible debenture to Peak One Opportunity Fund at a 15% original issue discount, recei | Oct 8, 2026 |
| FULC | S-4/A | neutral | 5/10 | Fulcrum Therapeutics (FULC) filed Amendment No. 1 to its S-4 registration statement on October 8, 2026, in connection wi | Oct 8, 2026 |
| PASG | S-4/A | bearish | 6/10 | Passage Bio (PASG) filed Amendment No. 4 to its S-4 registration statement for the proposed reverse merger with Remix Th | Oct 8, 2026 |
| AARD | 3 | neutral | 1/10 | Zhongwei Zhang filed an initial statement of beneficial ownership (Form 3) with the SEC, disclosing his position as a re | Oct 8, 2026 |
| PCRX | SC TO-C | bullish | 7/10 | Viatris Inc. announced an agreement to acquire Pacira BioSciences through a tender offer by its wholly owned subsidiary, | Oct 8, 2026 |
| PCVX | 424B5 | bearish | 6/10 | Vaxcyte is raising $500M (up to $575M with overallotment) via 1.50% convertible senior notes due 2032, with a concurrent | Oct 8, 2026 |
| PCVX | 424B5 | bearish | 6/10 | Vaxcyte is raising ~$474M in a common stock and pre-funded warrant offering priced at $64.00/share (4% discount to the $ | Oct 8, 2026 |
| NSRX | 6-K | neutral | 2/10 | Nasus Pharma held its Annual and Special General Meeting of Shareholders on October 8, 2026. All agenda items were appro | Oct 8, 2026 |
| OCUL | 144 | neutral | 2/10 | Todd Anderman, an Officer of Ocular Therapeutix, filed a Form 144 notice of intent to sell 11,984 shares of common stock | Oct 8, 2026 |
| JAGX | DEF 14A | bearish | 8/10 | Jaguar Health is holding a special meeting on November 6, 2026, to seek stockholder approval for six proposals that are | Oct 8, 2026 |
| ZTS | 8-K | neutral | 2/10 | Zoetis declared a Q4 2026 dividend of $0.53 per share, payable December 1, 2026 to holders of record as of October 30, 2 | Oct 8, 2026 |
| TENX | 8-K | neutral | 5/10 | Tenax Therapeutics filed an 8-K announcing a temporary pause in enrollment of its Phase 3 LEVEL-2 trial of TNX-103 (oral | Oct 8, 2026 |
| AARD | 8-K | neutral | 2/10 | Aardvark Therapeutics appointed David (Zhongwei) Zhang, Ph.D., MBA, as a Class II independent director, effective Octobe | Oct 8, 2026 |
| XRTX | 6-K | neutral | 3/10 | XORTX announced plans to file a Clinical Trial Application (CTA) with Health Canada for its XRx-026 gout program (XORLO) | Oct 8, 2026 |
| VREOF | 8-K | bullish | 6/10 | Vireo Growth Inc. (VREOF) subsidiaries closed a $60M term loan with Needham Bank on October 2, 2026, using proceeds to r | Oct 8, 2026 |
| CDT | SC 13G/A | bearish | 5/10 | Primary Development Fund (Cayman) SPC and related entities filed an exit Schedule 13G/A, disclosing they have ceased to | Oct 8, 2026 |
| JAZZ | 144 | neutral | 2/10 | Director Anne O'Riordan filed a Form 144 notice of intent to sell 14,687 shares of Jazz Pharmaceuticals common stock, wi | Oct 8, 2026 |
| BDRX | 6-K | neutral | 2/10 | Biodexa Pharmaceuticals announced a mandatory ratio change for its American Depositary Shares (ADSs), effective as a 1-f | Oct 8, 2026 |
| BOLD | S-4 | bearish | 7/10 | Boundless Bio (BOLD) filed an S-4 registration statement for a reverse merger with privately-held Serapha Bio. The combi | Oct 8, 2026 |
| TEVA | 3 | neutral | 2/10 | Dov Bergwerk filed a Form 3 initial statement of beneficial ownership upon becoming Interim Chief Legal Officer of Teva | Oct 8, 2026 |
| BHST | 6-K | neutral | 4/10 | BioHarvest Sciences announced a key milestone with partner Tate & Lyle in their next-generation sweetener development pr | Oct 8, 2026 |
| SXTC | 6-K | bearish | 6/10 | China SXT Pharmaceuticals announced a $12 million registered direct offering of 8,000,000 Class A ordinary shares at $1. | Oct 8, 2026 |
| GSK | 6-K | neutral | 1/10 | GSK filed a 6-K disclosing that independent Non-Executive Director Wendy Becker CBE has been appointed as a Non-Executiv | Oct 8, 2026 |
| NNVC | DEF 14A | neutral | 3/10 | NanoViricides filed its definitive proxy statement for the 2026 Annual Meeting, seeking re-election of three directors ( | Oct 8, 2026 |